Prithviraj Bose, MD

A practical approach to patient monitoring, with a focus on assessing treatment efficacy and individualized patient care.

A review of available treatments, treatment selection, and treatment sequencing for patients with PV as informed by clinical trial data.

Subject matter expert reviews biological mechanisms underpinning myeloproliferative neoplasms and standard-of-care risk assessment for patients with PV.

Dr Bose shares his initial impressions of a PV patient case before discussing typical patient presentation and criteria for PV diagnosis.

Prithviraj Bose, MD introduces a polycythemia vera (PV) patient case featuring a 67-year-old man presenting with frequent headaches and dizziness.

Description: Before closing out his discussion on polycythemia vera management, Prithviraj Bose, MD, shares excitement for emerging therapeutics in this setting.

Expert perspectives on long-term management of patients with polycythemia vera, with regard for the risk of developing secondary MF or AML.

In discussing the role of ruxolitinib in HU-resistant or intolerant PV, expert Prithviraj Bose, MD, highlights data from the RESPONSE and RESPONSE-2 clinical trials.

Considerations for therapy when patients with polycythemia vera experience hydroxyurea resistance or intolerance.

A comprehensive review of the treatment armamentarium for polycythemia vera, as well as strategies to monitor patients on therapy in this setting.

Expert Prithviraj Bose, MD, reviews standard practices in diagnosing and risk stratifying uncontrolled polycythemia vera in the context of a patient case.

The way I practice, personally, is that if they are older than 60 years, they are automatically high risk, and I will start hydroxyurea. In PV, being over 60 years and/or prior thrombosis automatically makes the patient high risk, so you should probably be starting a cytoreductive therapy.

Prithviraj Bose, MD, discusses differences in the safety profiles of ruxolitinib and fedratinib in the treatment of myelofibrosis.

Prithviraj Bose, MD, an associate professor in the Department of Leukemia, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, discusses a study exploring sotatercept (ACE-011) alone and in combination with ruxolitinib (Jakafi) in patients with myeloproliferative neoplasm (MPN)-associated myelofibrosis and anemia.